BLAVIAL
Approved
Jan 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
4/8 — Partial
ELSPAR (asparaginase) by Merck & Co. is (recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid l-asparagine into aspartic acid and ammonia. Approved for acute lymphoblastic leukemia, lymphoblastic lymphoma. First approved in 1978.
Drug data last refreshed 18h ago
Mechanism of Action
(recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of RYLAZE is based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of asparagine…
Indications (2)
Worked on ELSPAR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.